{"version":"1.0","provider_name":"MaaT Pharma","provider_url":"https:\/\/www.maatpharma.com\/fr\/","author_name":"MaaT Pharma","author_url":"https:\/\/www.maatpharma.com\/fr\/author\/maatpharma\/","title":"Actualit\u00e9s - MaaT Pharma","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"ujyplqWfZz\"><a href=\"https:\/\/www.maatpharma.com\/fr\/actualites\/\">Actualit\u00e9s<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.maatpharma.com\/fr\/actualites\/embed\/#?secret=ujyplqWfZz\" width=\"600\" height=\"338\" title=\"\u00ab\u00a0Actualit\u00e9s\u00a0\u00bb &#8212; MaaT Pharma\" data-secret=\"ujyplqWfZz\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"Am\u00e9liorer la survie des patients gr\u00e2ce \u00e0 une immunomodulation innovante Nous sommes une soci\u00e9t\u00e9 en phase clinique avanc\u00e9e, d\u00e9veloppant des m\u00e9dicaments bas\u00e9s sur le microbiote pour moduler le syst\u00e8me immunitaire et am\u00e9liorer la survie des patients atteints de cancer. D\u00e9couvrir nos actualit\u00e9s Profil de la soci\u00e9t\u00e9 Communiqu\u00e9s de presse MaaT Pharma dans les m\u00e9dias Posters Menu Profil de la Soci\u00e9t\u00e9 MaaT Pharma est une soci\u00e9t\u00e9 de biotechnologie en phase clinique avanc\u00e9e, leader dans le d\u00e9veloppement de m\u00e9dicaments issus du microbiote intestinal d\u00e9di\u00e9s \u00e0 moduler le syst\u00e8me immunitaire des patients atteints de cancer et \u00e0 am\u00e9liorer leur survie. Soutenue par une \u00e9quipe experte qui s\u2019engage \u00e0 faire la diff\u00e9rence pour les patients du monde entier, la Soci\u00e9t\u00e9 a \u00e9t\u00e9 fond\u00e9e en 2014 et est bas\u00e9e \u00e0 Lyon en France.Pionni\u00e8re dans son domaine, MaaT Pharma a franchi en janvier 2025 une \u00e9tape majeure dans son d\u00e9veloppement avec des r\u00e9sultats principaux positifs pour son essai clinique de Phase 3 \u00e9valuant son candidat-m\u00e9dicament immunomodulateur bas\u00e9 sur le microbiote intestinal en oncologie. Gr\u00e2ce \u00e0 ses technologies propri\u00e9taires de \u00ab pooling \u00bb (combinaison de dons de microbiotes sains) et de co-culture microbienne, MaaT Pharma d\u00e9veloppe des m\u00e9dicaments standardis\u00e9s \u00e0 haute diversit\u00e9 bact\u00e9rienne, visant \u00e0 am\u00e9liorer la survie des patients atteints de cancer. MaaT Pharma est cot\u00e9e sur Euronext Paris (MAAT) depuis 2021. Communiqu\u00e9s de presse Press Releases April 1st, 2026: MaaT Pharma Announces Publication of Retrospective Data in Third-Line Acute GvHD from the CHRONOS Study in Bone Marrow Transplantation Journal Press Releases March 31, 2026: MaaT Pharma Announces 2025 Annual Results and Provides Business Updates Press Releases March 23, 2026: MaaT Pharma Presents the ARES Phase 3 Pivotal Trial Final Data During the Presidential Plenary Session at the 52nd Annual Meeting of the European Society for Bone and Marrow Transplantation Press Releases March 9, 2026: MaaT Pharma to Present Four Abstracts at the 52nd European Bone Marrow Transplantation Annual Meeting and to Highlight Clinigen-Hosted Industry Symposium on acute GvHD Management Press Releases February 3, 2026: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Voir plus MaaT Pharma dans les m\u00e9dias Media April 1, 2026: Third-Line Therapy Shows Limited Efficacy in Real-World aGVHD Population &#8211; Cancer Network Media March 23, 2026: Microbiome Therapy Achieves High ORR and Survival in Acute GI GVHD &#8211; Targeted Oncology Media January 29, 2026: Premi\u00e8re th\u00e9rapie standardis\u00e9e en vue dans le microbiote en oncologie pour MaaT Pharma &#8211; Les Echos Investir (French Only) Media January 26, 2026: Le Journal des biotechs : Herv\u00e9 Affagard, MaaT Pharma &#8211; Boursorama (French Only) Media December 22, 2025: Interview of Herv\u00e9 Affagard &#8211; CEO and Co-Founder, MaaT Pharma &#8211; Pharma Boardroom Media December 9, 2025: ASH 2025: MaaT Pharma&#039;s microbiome based treatment for refractory GVHD is in front of EMA right now for a possible 2026 approval &#8211; the pivotal data was presented in an oral at ASH this week &#8211; Biotech TV Voir plus Vid\u00e9o Media Replay: KOL insights and MaaT013 Data from ASH 2024 Meeting Videos R&amp;D Day 2022 replay Videos H.C Wainwright Bioconnect 2022 conference replay Videos Investors Webcast &#8211; 12\/13\/21 &#8211; Corporate Update Videos IABS Bioaster &#8211; FMT WEBINAR Videos EY : Prix de l&#039;Entrepreneur de l&#039;Ann\u00e9e Posters Posters MaaT013 Pooled Fecal Microbiotherapy Improves Gastrointestinal Physiology And Controls Inflammation Which Delays GvHD In A Proof-Of-Concept Humanized Mouse Study Posters MaaT034, a new co-cultured microbiome ecosystem therapy candidate, potentiates anti-PD1 mediated antitumoral activity in germ-free mice Posters MaaT034, a new co-cultured microbiome ecosystem therapy candidate, safely colonizes the gastro-intestinal tract of germ-free mice to restore a healthy gut physiology and stimulates immunity Posters Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from Early Access Program in Europe Posters MaaT033 to ensure optimal intestinal microbiota to improve survival of patients receiving allo-HSCT: PHOEBUS trial Posters PHOEBUS Trial: an international, randomized, double-blind, multicenter phase IIb study evaluating MaaT033, oral allogeneic fecal microbiotherapy, in patients undergoing allo-HSCT to improve overall survival. SEHH Congress (Spanish only) Archives"}